Your browser is no longer supported. Please, upgrade your browser.
Settings
ZGNX Zogenix, Inc. daily Stock Chart
ZGNX [NASD]
Zogenix, Inc.
Index- P/E- EPS (ttm)-9.43 Insider Own0.20% Shs Outstand48.19M Perf Week-4.33%
Market Cap1.53B Forward P/E- EPS next Y-2.49 Insider Trans-21.65% Shs Float43.58M Perf Month-9.91%
Income-410.10M PEG- EPS next Q-1.00 Inst Own90.44% Short Float16.63% Perf Quarter13.70%
Sales4.90M P/S312.78 EPS this Y-198.20% Inst Trans19.31% Short Ratio6.88 Perf Half Y-46.54%
Book/sh9.35 P/B2.97 EPS next Y26.50% ROA-80.20% Target Price49.18 Perf Year-41.76%
Cash/sh7.62 P/C3.65 EPS next 5Y8.80% ROE-116.20% 52W Range16.65 - 57.22 Perf YTD-46.65%
Dividend- P/FCF- EPS past 5Y-37.00% ROI-175.40% 52W High-51.40% Beta1.72
Dividend %- Quick Ratio5.40 Sales past 5Y-33.90% Gross Margin- 52W Low67.03% ATR1.89
Employees141 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)47.59 Volatility4.66% 7.34%
OptionableYes Debt/Eq0.00 EPS Q/Q35.80% Profit Margin- Rel Volume0.55 Prev Close28.28
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume1.05M Price27.81
Recom1.70 SMA20-1.99% SMA50-2.28% SMA200-24.00% Volume578,953 Change-1.66%
Mar-06-20Initiated Citigroup Neutral $27
Feb-07-20Reiterated Needham Buy $58 → $54
Feb-07-20Downgrade Ladenburg Thalmann Buy → Neutral $35
Oct-21-19Initiated Needham Buy $58
Jun-27-19Upgrade Guggenheim Neutral → Buy $40 → $64
Apr-09-19Downgrade Guggenheim Buy → Neutral
Nov-05-18Initiated Piper Jaffray Overweight
Sep-14-18Initiated BofA/Merrill Buy $63
Sep-12-18Initiated Northland Capital Outperform $70
Sep-07-18Initiated B. Riley FBR Buy $116
Aug-23-18Initiated Ladenburg Thalmann Buy $71
Aug-15-18Resumed Stifel Buy $65 → $69
Jul-13-18Reiterated Stifel Buy $55 → $65
Nov-27-17Initiated JMP Securities Mkt Outperform
Oct-03-17Reiterated Mizuho Buy $28 → $51
Sep-29-17Upgrade William Blair Mkt Perform → Outperform
Oct-04-16Resumed Leerink Partners Outperform $17
Aug-11-15Reiterated Oppenheimer Outperform $20 → $23
Jul-15-15Reiterated Brean Capital Buy $20 → $28
Apr-22-15Initiated Piper Jaffray Overweight $2.50
Jul-05-20 03:45PM  
Jul-02-20 08:53AM  
Jul-01-20 09:43AM  
07:00AM  
Jun-29-20 06:53PM  
09:07AM  
Jun-26-20 10:48AM  
08:28AM  
01:27AM  
Jun-25-20 11:05PM  
08:49PM  
08:04PM  
08:26AM  
Jun-21-20 02:53PM  
Jun-19-20 10:09PM  
Jun-12-20 08:00AM  
Jun-10-20 06:19AM  
Jun-03-20 03:10AM  
May-28-20 11:24AM  
May-27-20 09:37PM  
May-15-20 08:00AM  
May-06-20 06:00PM  
08:00AM  
May-05-20 07:05PM  
04:01PM  
May-04-20 08:55AM  
Apr-28-20 12:56PM  
08:00AM  
Apr-20-20 08:00AM  
Apr-16-20 09:46AM  
Apr-15-20 08:00AM  
Apr-07-20 02:16PM  
Mar-29-20 12:31PM  
Mar-24-20 07:52AM  
Mar-21-20 09:08AM  
Mar-06-20 04:05PM  
Mar-05-20 11:09AM  
Mar-03-20 09:05PM  
05:07PM  
Mar-02-20 04:01PM  
Feb-28-20 07:28AM  
Feb-27-20 04:27PM  
08:00AM  
Feb-24-20 08:00AM  
Feb-11-20 11:27AM  
Feb-07-20 04:14PM  
07:32AM  
Feb-06-20 04:01PM  
Jan-23-20 12:18PM  
Dec-26-19 11:53AM  
Dec-17-19 07:04PM  
Dec-05-19 08:15AM  
Dec-04-19 12:42PM  
Dec-02-19 04:01PM  
08:00AM  
Nov-27-19 08:00AM  
Nov-25-19 09:13AM  
08:00AM  
Nov-21-19 02:42PM  
Nov-18-19 04:43PM  
Nov-12-19 08:00AM  
Nov-07-19 07:35PM  
04:01PM  
Oct-31-19 08:00AM  
Oct-25-19 09:00AM  
Oct-21-19 10:02AM  
08:00AM  
Oct-11-19 01:33PM  
Oct-08-19 08:28PM  
Oct-07-19 08:00AM  
Sep-26-19 07:00AM  
Sep-23-19 05:23PM  
Sep-18-19 08:49PM  
Sep-16-19 05:10PM  
Sep-11-19 09:00PM  
Sep-09-19 07:20PM  
08:00AM  
Sep-07-19 02:59PM  
Sep-06-19 03:38PM  
Sep-04-19 09:04PM  
Sep-03-19 02:49PM  
02:00PM  
Aug-30-19 10:59AM  
Aug-29-19 10:19AM  
Aug-26-19 04:36PM  
04:09PM  
09:03AM  
08:12AM  
07:00AM  
Aug-22-19 08:36AM  
Aug-12-19 07:15PM  
Aug-06-19 10:24PM  
Jul-31-19 01:48PM  
Jul-30-19 08:00AM  
Jul-29-19 08:33PM  
Jul-17-19 06:58AM  
Jul-08-19 06:29PM  
08:00AM  
Jul-07-19 07:45AM  
Jul-05-19 10:15PM  
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERJul 02Option Exercise0.003,750010,232Jul 06 04:37 PM
Galer Bradley S.EVP/Chief Medical OfficerJun 25Option Exercise0.0010,000020,015Jun 29 09:53 PM
Farfel Gail MEVP/Chief Development OfficerJun 25Option Exercise0.008,750014,223Jun 29 09:54 PM
Farfel Gail MEVP/Chief Development OfficerMay 12Sale28.212,57372,5845,048May 13 05:39 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMay 08Buy25.451,00025,4505,913May 11 06:18 PM
WIGGINS MARK CDirectorMar 23Buy20.482,50051,1962,500Mar 24 04:38 PM
FARR STEPHEN JPresident and CEOMar 19Option Exercise10.359,66199,99165,251Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 19Sale18.516,158113,96455,590Mar 20 04:01 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 18Buy19.691,00019,68510,015Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 15Option Exercise0.0010,000064,228Mar 17 07:25 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 15Option Exercise0.003,59509,573Mar 17 07:25 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMar 15Option Exercise0.002,03205,517Mar 17 07:25 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Mar 15Option Exercise0.003,59504,207Mar 17 07:24 PM
Farfel Gail MEVP/Chief Development OfficerMar 15Option Exercise0.003,65708,317Mar 17 07:24 PM
GARNER CAM LDirectorMar 13Buy21.838,000174,6478,000Mar 18 05:48 PM
FARR STEPHEN JPresident and CEOJan 08Option Exercise10.3934,225355,58290,933Jan 10 04:15 PM
FARR STEPHEN JPresident and CEOJan 08Sale51.8934,2251,775,92156,708Jan 10 04:15 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jan 02Option Exercise10.3522,500232,87523,887Jan 03 04:13 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jan 02Sale51.7922,5001,165,3401,387Jan 03 04:13 PM
BREITMEYER JAMES BDirectorDec 16Option Exercise8.995,00044,9506,250Dec 18 04:07 PM
BREITMEYER JAMES BDirectorDec 16Sale50.005,000250,0001,250Dec 18 04:07 PM
BREITMEYER JAMES BDirectorNov 25Option Exercise8.995,00044,9506,250Nov 27 04:13 PM
FARR STEPHEN JPresident and CEONov 25Option Exercise10.3534,225354,22990,752Nov 27 04:14 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Nov 25Option Exercise10.3515,000155,25016,387Nov 27 04:14 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Nov 25Sale48.0015,000720,0001,387Nov 27 04:14 PM
FARR STEPHEN JPresident and CEONov 25Sale50.0034,2251,711,25056,527Nov 27 04:14 PM
BREITMEYER JAMES BDirectorNov 25Sale50.005,000250,0001,250Nov 27 04:13 PM
FARR STEPHEN JPresident and CEOAug 29Option Exercise20.005,000100,00060,158Aug 30 04:10 PM
Farfel Gail MEVP/Chief Development OfficerAug 22Sale52.003,446179,1924,891Aug 23 04:09 PM
WIGGINS MARK CDirectorAug 09Option Exercise15.046,25094,0006,250Aug 12 05:51 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Aug 09Option Exercise10.3515,000155,25016,387Aug 12 05:51 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Aug 09Sale50.0015,000750,0001,387Aug 12 05:51 PM
WIGGINS MARK CDirectorAug 09Sale50.006,250312,5000Aug 12 05:51 PM